---
layout: default
title: Clomifene
parent: 僅模型預測 (L5)
nav_order: 78
evidence_level: L5
indication_count: 10
---

# Clomifene
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Clomifene: From Anovulatory Infertility to 46,XY Disorder of Sex Development Due to Testicular Steroidogenesis Defect

## One-Sentence Summary

Clomifene is a selective estrogen receptor modulator (SERM) widely established in clinical practice for inducing ovulation in women with anovulatory infertility. The TxGNN model assigns its highest score (99.90%) to **46,XY Disorder of Sex Development Due to Testicular Steroidogenesis Defect**, yet this direction is currently supported by **0 clinical trials** and **0 publications**. While a superficial mechanistic link exists through the hypothalamic-pituitary-gonadal (HPG) axis, the core biology of this condition renders the prediction biologically implausible — this high score most likely reflects knowledge graph topology rather than therapeutic opportunity.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Ovulation induction in anovulatory infertility (established clinical use; no Philippines registration on record) |
| Predicted New Indication | 46,XY Disorder of Sex Development Due to Testicular Steroidogenesis Defect |
| TxGNN Prediction Score | 99.90% |
| Evidence Level | L5 |
| Philippines Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

Clomifene is a non-steroidal SERM that competitively antagonises estrogen receptors at the hypothalamus. By blocking estrogen's negative feedback on the hypothalamic–pituitary axis, Clomifene increases GnRH pulse frequency, driving a rise in pituitary FSH and LH secretion. In women, this stimulates follicular development and triggers ovulation. In men, the same upstream LH surge theoretically stimulates testicular Leydig cells to produce testosterone — a mechanism already explored in male hypogonadism and male-factor infertility contexts.

The predicted indication, 46,XY DSD due to testicular steroidogenesis defect, sits within the same HPG axis that Clomifene acts upon. The TxGNN knowledge graph likely captured the structural proximity between Clomifene's gonadotropin-stimulating nodes and the testicular steroidogenesis pathway, generating a high prediction score. On the surface, one might reason: elevated LH → stimulated Leydig cells → increased steroidogenesis attempt.

However, this reasoning breaks down at the critical step. The defining pathology of this condition is enzymatic dysfunction at one or more steps of the steroidogenesis cascade — StAR protein deficiency, CYP11A1 loss, HSD3B2 mutations, or similar defects. Boosting the upstream hormonal signal (LH) cannot circumvent broken downstream enzymatic machinery. No amount of gonadotropin stimulation will restore steroid output when the conversion enzymes are non-functional. The evidence pack itself flags this: *"機轉關聯極弱。TxGNN 高分可能源於 KG 中生殖軸節點的結構相似性，而非生物學合理性。"* (mechanistic link is extremely weak; the high score likely originates from reproductive axis node structural similarity in the KG, not biological plausibility). This assessment is consistent with the complete absence of any clinical or preclinical literature for this pairing.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

> **Note:** Across all 10 top-ranked TxGNN predictions for Clomifene, only one prediction has any supporting literature: **Ovarian Remnant Syndrome (rank 10)**, with a single 1990 case series ([PMID 2216258](https://pubmed.ncbi.nlm.nih.gov/2216258/)) describing Clomifene citrate stimulation as a *diagnostic* adjunct — not a therapeutic intervention — for localising residual ovarian tissue post-bilateral oophorectomy. This reflects the limited evidence base across all predicted new indications.

---

## Safety Considerations

> Please refer to the package insert for safety information.

Detailed warnings, contraindications, and drug interaction data are not available in the current evidence pack. Regulatory label review (Philippines FDA or international equivalents) is required before any clinical assessment can proceed.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Despite a near-perfect TxGNN model score, the fundamental biology of 46,XY DSD due to testicular steroidogenesis defect is incompatible with Clomifene's mechanism of action — elevated gonadotropins cannot rescue downstream enzyme defects — and there is zero supporting clinical or preclinical evidence (L5). Furthermore, Clomifene has no Philippines regulatory presence (0 registrations), and complete safety data are currently unavailable.

**To proceed, the following is needed:**

- **Mechanistic validation:** Preclinical evidence (cell line or animal model) demonstrating any phenotypic benefit of LH/FSH elevation in the presence of specific steroidogenic enzyme defects (e.g., StAR, CYP11A1, HSD3B2 mutations)
- **Safety data recovery:** Retrieve full package insert from an international regulatory authority (FDA, EMA, or PMDA) to complete key warnings, contraindications, and DDI profiling — currently a blocking data gap (DG001)
- **MOA data recovery:** Confirm pharmacological mechanism from DrugBank API (DG002) to support any future mechanistic linkage analysis
- **Broader prediction review:** Consider deprioritising all 10 current top predictions, which span structural anomalies (vaginal septa), chromosomal copy-number variants, and complex genetic syndromes — none have a clear biological entry point for a SERM. A targeted review of Clomifene's established uses (anovulatory infertility, male hypogonadism, PCOS) as seeds for related-indication repurposing is recommended instead
- **Philippines regulatory pathway:** If any repurposing direction gains preclinical or clinical traction, a Philippines FDA registration pathway assessment will be required given current zero-registration status

---

> ⚠️ **Disclaimer:** This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

